Trial Profile
A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase II/III study of Rituximab in Patients with Systemic Lupus Erythematosus
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 12 May 2016
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Systemic lupus erythematosus
- Focus Therapeutic Use
- Sponsors Zenyaku Kogyo
- 06 Dec 2010 Status changed from active, no longer recruiting to completed as reported by University Hospital Medical Information Network - Japan.
- 16 Oct 2009 New trial record.